CompletedNot Applicable

Avastin for PDR (Proliferative Diabetic Retinopathy)

United States20 participantsStarted 2009-06

Plain-language summary

The purpose of this study is to determine the effect of anti-VEGF drug (Avastin) adminstration in eyes prior to surgical treatment for Traction retinal detachment (TRD) in patients with Proliferative Diabetic Retinopathy (PDR).

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Active fibrovascular proliferation due to PDR with TRD given pre-operative clearance for pars plana vitrectomy (PPV) and TRD repair. Exclusion Criteria: * Dense vitreous hemorrhage * Inability to follow-up for surgery within 3-7 days after intravitreal injection * History of stroke, thromboembolic event, or heart attack within the last 6 months * Less than 18 years of age * Pregnancy

What they're measuring

The Effect of an Anti-VEGF (Vascular Endothelial Growth Factor) Agent, Bevacizumab, on Levels of Vitreous and Aqueous Growth Factor Levels (pg/mL) in Eyes With Traction Retinal Detachment Due to PDR

Timeframe: 3 months after last surgery

Trial details

NCT IDNCT01270542

SponsorUniversity of Southern California

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2011-07

Results submitted2014-05-19

View on ClinicalTrials.gov More Retinal Detachment trials